Dr. Lin on Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL
November 16th 2022Richard J. Lin, MD, PhD, discusses the manufacturing considerations that factor into the CAR T-cell decision-making process in diffuse large B-cell lymphoma, the importance of open communication between community and referral physicians, and how early referral leads to optimal patient outcomes with CAR T-cell therapy.
Sequencing Strategies, Improving QOL Are Top Priorities in Neuroendocrine Neoplasm Treatment
November 10th 2022Diane Reidy-Lagunes, MD, discussed the role of next-generation sequencing paired with systemic therapies and the option of peptide receptor radionuclide therapy in neuroendocrine malignancies.
Frontline Setting Boasts Multiple Treatment Options for Patients With ALL
Clinicians treating patients with newly diagnosed acute lymphocytic leukemia now have multiple options at their disposal, including tyrosine kinase inhibitors, blinatumomab, and multiagent chemotherapy-based regimens, with more options aiming to enter the treatment paradigm.
CAR T-Cell Therapy Proves Effective in First Trial in Patients with Resistant Multiple Myeloma
October 3rd 2022Study establishes rationale for combination approaches targeting multiple proteins — therapy produces responses in 70% of study participants, including those who who relapsed after prior CAR T therapy.
Zanidatamab Zovodotin Showcases Promising Safety, Activity in HER2+ Solid Cancers
Zanidatamab zovodotin was found to produce encouraging responses and to have a manageable toxicity profile when used as a monotherapy in heavily pretreated patients with HER2-positive solid cancers.
Enfortumab Vedotin Plus Pembrolizumab Produces Encouraging Responses in Metastatic Urothelial Cancer
September 12th 2022The combination of enfortumab vedotin and pembrolizumab elicited a high overall response rate and a manageable safety profile in patients with locally advanced or metastatic urothelial cancer.
Lenvatinib/Pembrolizumab Combo Improves Survival, Responses in Advanced Endometrial Cancer
September 11th 2022Lenvatinib plus pembrolizumab maintained clinically meaningful benefits in outcomes vs physician’s choice of therapy for patients with advanced endometrial cancer who received prior platinum-based chemotherapy.
Adjuvant Nivolumab Plus Ipilimumab Fails to Improve DFS in Localized, High-Risk RCC
September 11th 2022The combination of adjuvant nivolumab and ipilimumab did not elicit a significant disease-free survival benefit vs placebo in patients with localized, renal cell carcinoma at high risk for relapse after nephrectomy.
Advances in Breast and Gastrointestinal Cancers at ESMO 2022: Drs Rugo and Abou-Alfa
September 10th 2022OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Low Unresectable or Metastatic Breast Cancer
September 5th 2022Dr Modi discusses the significance of the FDA approval of trastuzumab deruxtecan in metastatic HER2-low breast cancer, pivotal efficacy and safety data from the DESTINY-Breast04 trial, and how these findings pave the way for further progress across cancer therapy.